started · updated
Moderna's mFlusiva mRNA Flu Vaccine Approved by US FDA
The U.S. Food and Drug Administration has granted approval to Moderna’s mFlusiva, the first seasonal influenza vaccine that uses messenger‑RNA technology. The approval covers adults aged 50‑64 with full approval based on a late‑stage trial of about 40,000 participants that showed roughly a 27 % reduction in flu cases compared with a standard vaccine. Adults 65 and older receive accelerated approval, relying on a smaller study that demonstrated a strong immune response versus a high‑dose flu shot, with a confirmatory trial required. No major safety concerns were identified; the most common adverse events were mild injection‑site pain, fever, headache, fatigue and muscle aches. An independent FDA advisory committee voted unanimously in June to recommend the vaccine. After an earlier refusal to file, the agency reversed its decision following industry pressure and a public dispute. Moderna expects limited supplies of mFlusiva to reach selected retailers for the 2026‑27 flu season. Health Secretary Robert F. Kennedy Jr. has publicly criticized mRNA vaccines, but the FDA’s approval marks a significant milestone for seasonal flu prevention in the United States.
Entities
Adults aged 50 and older · Food and Drug Administration · Food and Drug Administration (FDA) · Moderna · Moderna Inc. · Robert F. Kennedy Jr. · Stéphane Bancel · U.S. Food and Drug Administration · U.S. Food and Drug Administration (FDA) · United States · mFLUSIVA · mFlusiva (mRNA‑1010)
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 27 SOURCES] Moderna expects limited supplies of mFlusiva to be available at select retailers ahead of the 2026‑2027 flu season. thegardenmagazine.com · queondamagazine.com · thecrystaleyes.com · www.ksfr.org · press24.mk · +22 more
- [● 8 SOURCES] The approval followed earlier controversy, including a February decision by a senior FDA official to block the application, which was later reversed. www.netcost-security.fr · eldebate.com.ar · www.ksfr.org · press24.mk · americanbazaaronline.com · +3 more
- [● 32 SOURCES] The FDA approved Moderna's mFlusiva, the first mRNA-based seasonal influenza vaccine in the United States. thegardenmagazine.com · www.netcost-security.fr · queondamagazine.com · thecrystaleyes.com · eldebate.com.ar · +27 more
- [● 27 SOURCES] mFlusiva is indicated for adults aged 50 and older. thegardenmagazine.com · www.netcost-security.fr · queondamagazine.com · thecrystaleyes.com · eldebate.com.ar · +22 more
- [● 26 SOURCES] Full approval for adults 50‑64 was based on a trial of about 40,000 participants showing roughly a 27 % reduction in flu cases versus a standard vaccine. thegardenmagazine.com · queondamagazine.com · thecrystaleyes.com · www.ksfr.org · americanbazaaronline.com · +21 more
- [● 29 SOURCES] No major safety concerns were identified; the most common adverse events were mild‑to‑moderate injection‑site pain, fever, headache, fatigue and muscle aches. thegardenmagazine.com · queondamagazine.com · thecrystaleyes.com · www.ksfr.org · press24.mk · +24 more
- [● 26 SOURCES] Accelerated approval for adults 65+ was granted after a smaller study showed a strong immune response compared with a high‑dose flu vaccine. thegardenmagazine.com · queondamagazine.com · thecrystaleyes.com · www.ksfr.org · americanbazaaronline.com · +21 more
- [● 27 SOURCES] An independent FDA advisory committee unanimously recommended approval in June. thegardenmagazine.com · www.netcost-security.fr · queondamagazine.com · thecrystaleyes.com · eldebate.com.ar · +22 more
- [● 21 SOURCES] The FDA approved Moderna's mFlusiva, the first mRNA flu vaccine in the United States. thegardenmagazine.com · queondamagazine.com · thecrystaleyes.com · www.lootpress.com · www.netcost-security.fr · +16 more
- [● 16 SOURCES] The FDA initially declined to review Moderna’s application, then reversed its decision after industry pressure. www.lootpress.com · thecrystaleyes.com · www.ksfr.org · www.notiulti.com · press24.mk · +11 more
- [● 20 SOURCES] The approval covers adults aged 50 years and older. thegardenmagazine.com · www.lootpress.com · www.netcost-security.fr · queondamagazine.com · www.sbctv.gr · +15 more
- [● 20 SOURCES] Full approval for ages 50‑64 was based on a trial of about 40,000 participants that showed roughly a 27 % reduction in flu cases versus a standard vaccine. thegardenmagazine.com · www.lootpress.com · www.netcost-security.fr · queondamagazine.com · www.sbctv.gr · +15 more